First patient implanted in EVO implantable lens trial

The first patient has been implanted in an investigational clinical study of STAAR Surgical’s EVO ICL family of lenses, according to a press release.

EVO Visian IOLs are designed to treat a wide range of refractive error, including myopia, the release said.

The multicenter clinical evaluation will enroll patients at more than a dozen U.S. clinics. The first patient was implanted by Francis W. Price Jr., MD, at Price Vision Group in Indianapolis.

“Enrolling and implanting patients in the U.S. trial of our EVO family of implantable Collamer lenses is the next step in opening the U.S. market, the second largest market in the world for refractive vision correction, to our latest generation of lenses,” Caren Mason, president and CEO of STAAR Surgical, said in the release. “Surgeons outside the U.S. have implanted in excess of 750,000 of our EVO lenses in patients as the need for distance vision correction grows. We look forward to the U.S. study of our EVO lenses generating additional safety data on our implantable Collamer lenses.”

The first patient has been implanted in an investigational clinical study of STAAR Surgical’s EVO ICL family of lenses, according to a press release.

EVO Visian IOLs are designed to treat a wide range of refractive error, including myopia, the release said.

The multicenter clinical evaluation will enroll patients at more than a dozen U.S. clinics. The first patient was implanted by Francis W. Price Jr., MD, at Price Vision Group in Indianapolis.

“Enrolling and implanting patients in the U.S. trial of our EVO family of implantable Collamer lenses is the next step in opening the U.S. market, the second largest market in the world for refractive vision correction, to our latest generation of lenses,” Caren Mason, president and CEO of STAAR Surgical, said in the release. “Surgeons outside the U.S. have implanted in excess of 750,000 of our EVO lenses in patients as the need for distance vision correction grows. We look forward to the U.S. study of our EVO lenses generating additional safety data on our implantable Collamer lenses.”